NETTER-P: Lutathera in Adolescent Patients (12-17) with GEP-NETs and PPGLs

NETTER-P: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

CLINICALTRIALS.GOV IDENTIFIER: NCT04711135

DRUG/TREATMENT: Lutetium [177Lu] oxodotreotide/dotatate

PHASE: 1

STATUS: Recruiting

SPONSOR: Advanced Accelerator Applications (AAA)

Dr. Aman Chauhan Discusses "NETTER-P" Lutathera in Adolescent Patients

DESCRIPTION:

Advanced Accelerator Applications (AAA) is sponsoring a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT:

Novartis Pharmaceuticals

EMAIL: Novartis.email@novartis.com

PHONE: 1-888-669-6682